Goserelin drug data and news

Goserelin drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.

Generic name

Goserelin

Brand Names/Synonyms

Goserelin acetate; Goserelin acetate (JAN/USP); Zoladex

Indication

Breast cancer; Prostate carcinoma; Endometriosis

Sponsored links

Description

Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.

Pharmacology

The pharmacokinetics of ZOLADEX have been determined in both male and female healthy volunteers and patients. In these studies, ZOLADEX was administered as a single 250�g (aqueous solution) dose and as a single or multiple 3.6 mg depot dose by subcutaneous route.

Mechanism Of Action

ZOLADEX is a synthetic decapeptide analogue of LHRH. ZOLADEX acts as a potent inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels.

Goserelin News
(When available)

Procyon Shareholders Approve Cellpep Acquisition Feb 27, 2006
...in the US in 2008. The second product, Goserelin, is expected to be launched in Europe in 2008. "Today's vote confirmed the strong ... - International News Service,

Procyon Announces the Completion of the Acquisition of Cellpep SA ... Mar 1, 2006
The second product, Goserelin, is expected to be launched in Europe in 2008. With these late-stage products, Ambrilia Biopharma ... - PharmaLive.com (press release),

Repeat/Media Advisory: Procyon' Special Meeting of Shareholders ... Feb 22, 2006
The second product, goserelin, is expected to be launched in Europe in 2008. With this combined portfolio comprised of high-value ... - CCNMatthews (press release),

Gonadotropin-Releasing Hormone Anologue Prevents Ovarian Failure ... Feb 8, 2006
Researchers from Italy have reported that the administration of the gonadotropin releasing hormone analogue goserelin (Gn-RH) prevents ovarian failure in women ... - Cancer Consultants (press release),

Procyon Presents Preclinical Results with its Novel Tumor ... Feb 7, 2006
The second product, goserelin, is expected to be launched in Europe in 2008. With this combined portfolio comprised of high-value ... - CCNMatthews (press release),

Ovarian Suppression During Chemotherapy May Protect Ovarian ... Jan 27, 2006
...first dose of the GnRH analogue. The GnRH analogue used in this study was Zoladex® (goserelin). Patients enrolled at the beginning ... - Cancer Consultants (press release),

Procyon Biopharma to Acquire Cellpep SA Jan 19, 2006
Cellpep is also developing goserelin, an improved version of a prostate cancer drug as well as a fusion inhibitor for HIV and several other peptides. ... - TechFinance,

New Data Show Survival Benefit for Arimidex(TM) in Early Breast ... Dec 9, 2005
...including 'ARIMIDEX' (anastrozole), 'CASODEX' (bicalutamide), 'FASLODEX' (fulvestrant), 'NOLVADEX' (tamoxifen), 'ZOLADEX' (goserelin), 'TOMUDEX' (raltitrexed ... - news aktuell (Pressemitteilung),

Prostate cancer: awaiting innovation Dec 8, 2005
...hormone (LHRH) agonist monotherapy remains the most commonly used drug therapy for prostate cancer, and agents such as leuprolide and goserelin are considered ... - Pharmaceutical Business Review

AstraZeneca Provides Additional Support to Hurricane Victims Nov 17, 2005
...inhalation powder), RHINOCORT AQUA® (budesonide), SEROQUEL® (quetiapine fumarate), TOPROL-XL® (metoprolol succinate), ZOLADEX® (goserelin acetate implant ... - Yahoo! News (press release)

AstraZeneca Provides Additional Support to Hurricane Victims Nov 17, 2005
...powder), RHINOCORT AQUA(R) (budesonide), SEROQUEL(R) (quetiapine fumarate), TOPROL-XL(R) (metoprolol succinate), ZOLADEX(R) (goserelin acetate implant), ZOMIG(R ... - PR Newswire (press release),

Phase II Trial Suggests Benefit of Hormonal Therapy for Recurrent ... Oct 20, 2005
...results of a phase II clinical trial published in the British Journal of Cancer, the combination of Nolvadex® (tamoxifen) and Zoladex® (goserelin) was well ... - Cancer Consultants (press release),

Nolvadex® and Zoladex® Effective Palliation for Recurrent ... Oct 19, 2005
50% of patients with recurrent ovarian cancer had disease control for six months or more following treatment with Nolvadex (tamoxifen) and Zoladex (goserelin). ... - Cancer Consultants (press release),

Short-Term Hormone Therapy Can Improve Outlook for Early Prostate ... Oct 5, 2005
When compared with men treated by radiotherapy alone, men treated with three months of goserelin and flutamide prior to and during radiotherapy had a 35% lower ... - Newswise (press release)

Hormonal Therapy Added to Radiation Improves Prostate Cancer ... Oct 5, 2005
...in a larger clinical trial, they conducted a study comparing radiotherapy alone to radiotherapy plus androgen deprivation with Zoladex (goserelin) and Eulexin ... - MedPage Today,

Call to relax PBS restriction Oct 11, 2005
Men treated with six months of goserelin (Zoladex) and flutamide (Eulexin) before and during radiotherapy had their risk of relapse reduced by 44% compared ... - AustralianDoctor.com (subscription),

Call to relax PBS restriction 11 Oct 2005
Men treated with six months of goserelin (Zoladex) and flutamide (Eulexin) before and during radiotherapy had their risk of relapse reduced by 44% compared ... - AustralianDoctor.com (subscription),

AstraZeneca Receive Highly Coveted Frost & Sullivan Award ... Sep 20, 2005
...including 'ARIMIDEX' (anastrozole), 'CASODEX' (bicalutamide), 'FASLODEX' (fulvestrant), 'NOLVADEX' (tamoxifen), 'ZOLADEX' (goserelin), 'TOMUDEX' (raltitrexed ... - PR Newswire (press release),

New International Treatment Guidelines Verify Crucial Role of ' ... Sep 7, 2005
...including 'ARIMIDEX' (anastrozole), 'CASODEX' (bicalutamide), 'FASLODEX' (fulvestrant), 'NOLVADEX' (tamoxifen), 'ZOLADEX' (goserelin), 'TOMUDEX' (raltitrexed ... - news aktuell (Pressemitteilung),

AstraZeneca Pledges More Than $1 Million in Contributions and ... Sep 1, 2005
...inhalation powder), RHINOCORT AQUA® (budesonide), SEROQUEL® (quetiapine fumarate), TOPROL-XL® (metoprolol succinate), ZOLADEX® (goserelin acetate implant ... - Yahoo! News (press release)

AstraZeneca Pledges More Than $1 Million in Contributions and ... Sep 1, 2005
...powder), RHINOCORT AQUA(R) (budesonide), SEROQUEL(R) (quetiapine fumarate), TOPROL-XL(R) (metoprolol succinate), ZOLADEX(R) (goserelin acetate implant), ZOMIG(R ... - PR Newswire (press release),

Data Confirm Postmenopausal Women Taking Adjuvant Tamoxifen for ... Aug 4, 2005
...including 'ARIMIDEX' (anastrozole), 'CASODEX' (bicalutamide), 'FASLODEX' (fulvestrant), 'NOLVADEX' (tamoxifen), 'ZOLADEX' (goserelin), 'TOMUDEX' (raltitrexed ... - Presseportal (Pressemitteilung)

CMS Issues Interim Final Rule on Competitive Acquisition of ... Jul 19, 2005
...an LCA policy to injectable forms of leuprolide, which would have the effect of requiring vendors to supply the drug at the cost of goserelin regardless of the ... - Mondaq News Alerts <**results**>

Studies of Bone Health Jun 30, 2005
These include medicines that shut down the ovary and its production of estrogen, such as Zoladex (chemical name: goserelin) and Lupron (chemical name ... - Breastcancer.org,

Dosage Forms

supplied as a sterile and totally biodegradable D,L-lactic and glycolic acids copolymer (13.3-14.3 mg/dose) impregnated with goserelin acetate equivalent to 3.6 mg of goserelin in a disposable syringe device fitted with a 16-gauge hypodermic needle

Drug_Category

Antineoplastic Agents; Unclassified Therapeutic Agents (92:00.00); ATC:L02AE03

Absorption

inactive orally, rapidly absorbed following subcutaneous administration

Interactions

No formal drug-drug interaction studies have been performed. No confirmed interactions have been reported between ZOLADEX and other drugs

Toxicity

no experience of overdosage from clinical trials

Organisms Affected

Humans and other mammals

Chemical IUPAC Name

N-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-(carbamoylaminocarbamoyl)pyrrolidin-1-yl]carbonyl-4-guanidino-butyl]carbamoyl]-3-methyl-butyl]carbamoyl]-2-tert-butoxy-ethyl]carbamoyl]-2-(4-hydroxyphenyl)-ethyl]carbamoyl]-2-hydroxy-ethyl]carbamoyl]-2-(1H-indol-3-yl)ethyl]carbamoyl]-2-(3H-imidazol-4-yl)ethyl]-5-oxo-pyrrolidine-2-carboxamide

Chemical Formula

C59H84N18O14

Molecular Weight

1268.6403

Smiles String

Not Available

Melting Point

°C

Water Solubility

Soluble

State

off-white powder

LogP/Hphobicity

Not Available

Isoelectric Point

Not Available

Biotransformation

Hepatic

Half Life

4-5 hours

Protein Binding [%]

27.30%

RxList Link

RXlist

Sponsored links

Drug Reference

http://www.drugs.com/cons/Goserelin.html
http://www.rxlist.com/cgi/generic/goserel.htm

Drug Type

Approved Drug

Accession No

BIOD00113

CAS Registry Number

65807-02-5

KEGG Compound ID

C07614

PubChem ID

SID:9816

PharmGKB ID

Not Available

SwissProt ID

Not Available

GenBank ID

Not Available

Drug ID Number [DIN]

2225905